Analysts Set Expectations for CGEM Q1 Earnings

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Cullinan Therapeutics in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.74) per share for the quarter. The consensus estimate for Cullinan Therapeutics' current full-year earnings is ($3.12) per share. Leerink Partnrs also issued estimates for Cullinan Therapeutics' Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.84) EPS and Q4 2025 earnings at ($0.88) EPS.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.09.

A number of other equities research analysts also recently commented on the stock. HC Wainwright raised their price objective on shares of Cullinan Therapeutics from $28.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. UBS Group began coverage on Cullinan Therapeutics in a research report on Thursday, October 24th. They issued a "buy" rating and a $30.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $32.50.

Cullinan Therapeutics Price Performance

Shares of CGEM stock traded down $0.08 during midday trading on Friday, hitting $10.13. The company had a trading volume of 152,909 shares, compared to its average volume of 497,831. The stock has a market cap of $589.87 million, a price-to-earnings ratio of -3.56 and a beta of -0.16. The company's 50 day simple moving average is $11.42 and its 200 day simple moving average is $14.82. Cullinan Therapeutics has a 52-week low of $9.50 and a 52-week high of $30.19.

Insider Buying and Selling at Cullinan Therapeutics

In related news, CEO Nadim Ahmed sold 8,400 shares of the stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $11.87, for a total transaction of $99,708.00. Following the completion of the sale, the chief executive officer now owns 263,150 shares of the company's stock, valued at approximately $3,123,590.50. This represents a 3.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jennifer Michaelson sold 3,489 shares of Cullinan Therapeutics stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $12.52, for a total transaction of $43,682.28. Following the transaction, the insider now directly owns 104,453 shares in the company, valued at approximately $1,307,751.56. This trade represents a 3.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 20,582 shares of company stock worth $246,977. Corporate insiders own 6.07% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Amalgamated Bank raised its stake in shares of Cullinan Therapeutics by 97.3% during the third quarter. Amalgamated Bank now owns 1,768 shares of the company's stock valued at $30,000 after purchasing an additional 872 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Cullinan Therapeutics by 10.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,346 shares of the company's stock worth $150,000 after buying an additional 1,195 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Cullinan Therapeutics by 3.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,911 shares of the company's stock worth $1,187,000 after buying an additional 2,377 shares in the last quarter. New York State Common Retirement Fund grew its stake in shares of Cullinan Therapeutics by 32.9% during the fourth quarter. New York State Common Retirement Fund now owns 12,918 shares of the company's stock valued at $157,000 after acquiring an additional 3,200 shares in the last quarter. Finally, Harbor Capital Advisors Inc. grew its stake in shares of Cullinan Therapeutics by 22.2% during the third quarter. Harbor Capital Advisors Inc. now owns 21,362 shares of the company's stock valued at $358,000 after acquiring an additional 3,881 shares in the last quarter. Institutional investors and hedge funds own 86.31% of the company's stock.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.